Latest filing published 21 Jun 2023 for Bionik Laboratories Corp..
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -83.6%Entry US$0.61 · Close at T+365 US$0.10
- -34.6%Entry US$0.95 · Close at T+365 US$0.62
- -59.4%Entry US$3.20 · Close at T+365 US$1.30
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Remi Gaston-Dreyfus: trading record in brief
Remi Gaston-Dreyfus (board member) discloses dealings in Bionik Laboratories Corp. to SEC (Form 4). The record holds 15 filings, for trades running from 31 March 2018 to 13 June 2023.
The open-market record is one-sided, with 3 purchases worth €461k and not one sale. The amount is not disclosed for 1 filing. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 1 share grant and 2 option exercises. So far in 2023, the count stands at 1 purchase and no sales.
Clusters matter here: 1 out of 3 purchases overlapped with buying by a colleague within 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.
The latest filing, published on 21 June 2023, reports a transaction in Bionik Laboratories Corp. The latest purchase dates back some time: it was published 1,236 days ago, on 21 June 2023. Filings reach the SEC (Form 4) feed a median of 8 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Remi Gaston-Dreyfus
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 3,102,878 shares@ €0.556169.2% of flowCommon Stock, par value $0.001 per shareSEC:0001104659-23-073232:0
- 180,555 shares@ US$0.60100.0% of flowCommon Stock, par value $0.001 per shareSEC:0001104659-23-073229:0Canonical exit: 7 Sept 2023 (T+90)
- 77,887 shares@ €8.5799100.0% of flowCommon Stock, par value $0.001 per shareSEC:0001104659-22-073083:0
- 5,000 sharesCommon Stock, par value $0.001 per shareSEC:0001104659-21-149127:1
- 115,759 sharesCommon Stock, par value $0.001 per shareSEC:0001104659-21-149127:0
- 61,256 sharesCommon Stock, par value $0.001 per shareSEC:0001104659-21-149126:0
- 135,560 sharesCommon Stock, par value $0.001 per shareSEC:0001104659-21-149123:0Canonical exit: 24 Jun 2021 (T+90)
- 4,997 shares0Common StockSEC:0001104659-19-067939:0
- 76,225 shares@ US$6.800.0% of flowCommon StockSEC:0001144204-19-047100:0
- 106,358 shares@ US$3.760.0% of flowCommon StockSEC:0001144204-19-042003:0Canonical exit: 24 Nov 2019 (T+90)
- 197,234 shares@ US$3.89Common StockSEC:0001144204-19-018387:0
- 43,468,547 shares@ US$0.0513Common StockSEC:0001144204-18-040076:0
- 15,740,728 shares@ US$0.0625Common StockSEC:0001144204-18-036313:0
- 63,197,149 shares@ US$0.0625Common StockSEC:0001144204-18-019049:0
- 12,266,240 shares@ US$0.0625Common StockSEC:0001144204-18-019049:1
15 of 15 declarations